155 related articles for article (PubMed ID: 16258020)
1. Differential in vivo potencies of naltrexone and 6beta-naltrexol in the monkey.
Ko MC; Divin MF; Lee H; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2006 Feb; 316(2):772-9. PubMed ID: 16258020
[TBL] [Abstract][Full Text] [Related]
2. Comparison of naltrexone, 6alpha-naltrexol, and 6beta-naltrexol in morphine-dependent and in nondependent rhesus monkeys.
Li JX; McMahon LR; France CP
Psychopharmacology (Berl); 2008 Jan; 195(4):479-86. PubMed ID: 17874317
[TBL] [Abstract][Full Text] [Related]
3. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
Raehal KM; Lowery JJ; Bhamidipati CM; Paolino RM; Blair JR; Wang D; Sadée W; Bilsky EJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):1150-62. PubMed ID: 15716384
[TBL] [Abstract][Full Text] [Related]
4. Mu-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy.
Sirohi S; Kumar P; Yoburn BC
J Pharmacol Exp Ther; 2007 Nov; 323(2):701-7. PubMed ID: 17698975
[TBL] [Abstract][Full Text] [Related]
5. Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management.
Sadee W; Oberdick J; Wang Z
Molecules; 2020 Sep; 25(18):. PubMed ID: 32932935
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone.
Porter SJ; Somogyi AA; White JM
Addict Biol; 2002 Apr; 7(2):219-25. PubMed ID: 12006217
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-naïve and morphine-dependent mice.
Divin MF; Holden Ko MC; Traynor JR
Eur J Pharmacol; 2008 Mar; 583(1):48-55. PubMed ID: 18275956
[TBL] [Abstract][Full Text] [Related]
8. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.
Wang D; Raehal KM; Bilsky EJ; Sadée W
J Neurochem; 2001 Jun; 77(6):1590-600. PubMed ID: 11413242
[TBL] [Abstract][Full Text] [Related]
9. 6beta-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice.
Yancey-Wrona JE; Raymond TJ; Mercer HK; Sadée W; Bilsky EJ
Life Sci; 2009 Sep; 85(11-12):413-20. PubMed ID: 19583969
[TBL] [Abstract][Full Text] [Related]
10. The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity.
Sirohi S; Dighe SV; Madia PA; Yoburn BC
J Pharmacol Exp Ther; 2009 Aug; 330(2):513-9. PubMed ID: 19435929
[TBL] [Abstract][Full Text] [Related]
11. The role of opioid antagonist efficacy and constitutive opioid receptor activity in the opioid withdrawal syndrome in mice.
Navani DM; Sirohi S; Madia PA; Yoburn BC
Pharmacol Biochem Behav; 2011 Oct; 99(4):671-5. PubMed ID: 21736895
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes.
Pelotte AL; Smith RM; Ayestas M; Dersch CM; Bilsky EJ; Rothman RB; Deveau AM
Bioorg Med Chem Lett; 2009 May; 19(10):2811-4. PubMed ID: 19364645
[TBL] [Abstract][Full Text] [Related]
13. Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.
Divin MF; Bradbury FA; Carroll FI; Traynor JR
Br J Pharmacol; 2009 Apr; 156(7):1044-53. PubMed ID: 19220294
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of the antagonistic effects of 6 beta-naltrexol and naltrexone against morphine analgesia].
Yan LD; Gong ZH; Yao XJ; Qin BY
Yao Xue Xue Bao; 2003 Aug; 38(8):578-81. PubMed ID: 14628446
[TBL] [Abstract][Full Text] [Related]
15. 6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study.
Yancey-Wrona J; Dallaire B; Bilsky E; Bath B; Burkart J; Webster L; Magiera D; Yang X; Phelps M; Sadee W
Pain Med; 2011 Dec; 12(12):1727-37. PubMed ID: 22123184
[TBL] [Abstract][Full Text] [Related]
16. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
Wang D; Raehal KM; Lin ET; Lowery JJ; Kieffer BL; Bilsky EJ; Sadée W
J Pharmacol Exp Ther; 2004 Feb; 308(2):512-20. PubMed ID: 14600246
[TBL] [Abstract][Full Text] [Related]
17. In vivo characterization of the opioid antagonist nalmefene in mice.
Osborn MD; Lowery JJ; Skorput AG; Giuvelis D; Bilsky EJ
Life Sci; 2010 Apr; 86(15-16):624-30. PubMed ID: 20159022
[TBL] [Abstract][Full Text] [Related]
18. Thienorphine: receptor binding and behavioral effects in rhesus monkeys.
Li JX; Becker GL; Traynor JR; Gong ZH; France CP
J Pharmacol Exp Ther; 2007 Apr; 321(1):227-36. PubMed ID: 17220427
[TBL] [Abstract][Full Text] [Related]
19. The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours.
Kelly E; Mundell SJ; Sava A; Roth AL; Felici A; Maltby K; Nathan PJ; Bullmore ET; Henderson G
Psychopharmacology (Berl); 2015 Jan; 232(1):305-14. PubMed ID: 24973897
[TBL] [Abstract][Full Text] [Related]
20. The role of central mu opioid receptors in opioid-induced itch in primates.
Ko MC; Song MS; Edwards T; Lee H; Naughton NN
J Pharmacol Exp Ther; 2004 Jul; 310(1):169-76. PubMed ID: 15044556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
